May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Bevacizumab Binding to Human Sclera Post Topical Application
Author Affiliations & Notes
  • J. Y. Yu
    Ophthalmology, UPMC, Pittsburgh, Pennsylvania
  • M. Y. Kahook
    Ophthalmology, Rocky Mountain Lions Eye Institute/University of Colorado, Denver, Colorado
  • J. S. Schuman
    Ophthalmology, UPMC, Pittsburgh, Pennsylvania
  • N. SundarRaj
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • E. Guerriero
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • R. J. Noecker
    Ophthalmology, UPMC, Pittsburgh, Pennsylvania
  • Footnotes
    Commercial Relationships J.Y. Yu, None; M.Y. Kahook, None; J.S. Schuman, None; N. SundarRaj, None; E. Guerriero, None; R.J. Noecker, None.
  • Footnotes
    Support NIH Grant EY080908
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4815. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Y. Yu, M. Y. Kahook, J. S. Schuman, N. SundarRaj, E. Guerriero, R. J. Noecker; Bevacizumab Binding to Human Sclera Post Topical Application. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4815.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Bevacizumab (Avastin®, Genentech, California, USA), is an anti-angiogenesis medication used for cancer treatment and may have potential in modulating the fibrovascular response post trabeculectomy. This study will evaluate the amount of retained bevacizumab on scleral tissue after topical application.


Scleral bevacizumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) with the wells coated with avidin. Biotinylated bevacizumab was used as the primary antibody. Goat anti-human IgG conjugated to horseradish peroxidase as the secondary antibody. Four concentrations of biotinylated bevacizumab (1.25 mg, 0.6 mg, 0.3 mg and 0.125 mg per 0.05ml) as standards . The supernatant of human scleral tissue was treated with the biotinylated bevacizumab for 30 minutes prior to performing the ELISA. Concentrations of each supernatant tissue group were determined as a comparison to the standards.




Bevacizumab is retained in scleral tissue after topical application and may have a role in treating fibrovascular diseases of the ocular surface. Further studies are needed to better delineate optimal delivery technique and dosing.

Keywords: immunohistochemistry • sclera 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.